Evan Curcic is a client success manager at MMIT, developing market access solutions for our small-to-medium size client base. He works to onboard new clients to MMIT’s platforms and helps current clients get the most value out of MMIT’s solutions during all phases of their brand’s life cycle.
Q: How did you join the company?
A: When I first joined MMIT six years ago, I had a background primarily in software development and client service. Health care was just not an industry that I’d been exposed to yet, but I was a huge fan of B2B software as a service and working directly with clients. I had a friend who worked for MMIT’s top recruiting partner at the time who got me an interview and the rest is history. I’ve really enjoyed getting experience in the health care and market access industry, and I really love working in this space now.
Q: What’s your day to day like?
A: My day-to-day consists of partnership kickoff calls with new clients, therapeutic area briefs, data and lives methodology trainings, promotional project planning, consultative reporting engagement and datafeed structure and bridging overviews. My main goal is to help align our clients’ business objectives with the use of our solutions. I want them to feel confident and that they’re getting the utmost value from our engagements with them so they can do their jobs even better and be able to answer any of their market access business questions at any time.
Q: What are some of the challenges of your role?
A: Our job is not done just because we’ve sold a client our solutions. You have to give them a really positive experience off the bat, build trust, make sure they’re being heard and their needs are being met. Each account I work with has a different therapeutic area and slightly different goals they’re trying to achieve, and I’m also working with a lot clients primarily in the middle of launch, so one of my biggest challenges is making sure that I’m providing enough time for all of my clients and showing them all the same level of TLC.
Q: What are some of the larger projects you’re working on?
A: Like most companies, our large clients get a certain level of service and engagement, and rightfully so. I think what sets MMIT apart from our direct competitors in this niche is that for the past few years, we’ve really focused on trying to provide that same level of service and value to our small- and medium-sized clients as well. Just because a client may not have a massive contract with us or a huge spending budget doesn’t mean that they shouldn’t get the same level of service and attention that some other companies might only invest in their largest customers. I’ve directly had a hand in improving this process over the last few years by taking the experience I’ve gained working with our larger clients and bringing that to our small-to-medium segment with great support, collaboration and guidance from MMIT leadership.
Q: What market access trends should clients be looking out for?
A: When you’re talking about launching products, a lot of my clients are doing a ton of market research. Let’s say they’re in pre-launch mode, and they’re trying to get a good understanding of what some of the other analogs in that therapeutic area have gone through. What challenges has everyone else seen? What we’ve seen over the past few years is that things have progressively gotten a lot more restrictive. With that shift to higher utilization management out of launch, sometimes clients have to wait longer for payers and PBMs to make decisions. That’s where I believe MMIT shines, because that’s where our PAR (prior authorization and restriction) data can be very valuable. Clients are saying, ‘Hey, what are these prior authorization or step therapy challenges that other brands have faced, and are we going to see something similar?”
We’re even seeing some drastic shifts in restrictiveness year over year. Let’s say I’m launching a new product in a therapeutic area, and let’s say some of the big-name blockbuster drugs in that class were launched just four or five years ago. The restrictive climate of launch has shifted so quickly year-over-year, that even though those drugs are successful products, you may want to look at something more recent to compensate for some of those drastic yearly access climate changes.
Q: Any buzzworthy therapeutic areas to watch out for?
A: What we’re seeing happening with rare orphan disease drugs is really interesting. I’m starting to work with more manufacturers who are releasing these types of products. Unlike some other areas, payers and PBMs are making faster decisions there, so it’s interesting to watch as spending and FDA approval for those products shifts. For certain rare disease drugs that are solving a unique problem for a small population, we’re seeing them get coverage a little bit more quickly than they did five years ago, and that’s contrary to the level of restrictiveness we’re seeing in some other therapeutic areas of access.
Q: What’s your favorite part of your job?
A: Up to this point, I’ve worked with around 70 different pharma manufacturers. And through partnering with those clients, I’ve learned a ton in terms of what pharma is doing and focused on in terms of access at an aggregate level. I get a lot of satisfaction from providing insights to my clients in terms of how I’ve seen other folks do it (anonymously of course), and give them some options that let them pick and choose how they want to approach things using our solutions. I love being able to bring insight into our discussions that they find valuable and want to act on.
Q: What do you like to do outside of work?
A: I love spending time with my family, especially my wife and 2-year-old daughter. I’m also a huge live music fan and music nerd. I love sports and the outdoors as well. Any activity combining those things, I’m all about it.
by Carina Belles